表 3.
Logistic回归分析RA患者基线肌肉量减少的相关因素
Logistic regression analysis of factors related to baseline myopenia in RA patients
| Items | Univariate | Multivariate1 | Multivariate2 | |||||
| OR(95%CI) | P | OR(95%CI) | P | OR(95%CI) | P | |||
| ITIH3, inter-alpha trypsin inhibitor heavy chain 3; RA, rheumatoid arthritis; RF, rheumatoid factor; ACPA, anti-cyclic citrullinated protein antibodies; 28TJC, 28 tender joint counts; 28SJC, 28 swollen joint counts; PtGA, patient global assessment of disease activity; PrGA, physician global assessment of disease activity; VAS, visual analogue scale; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CDAI, clinical disease activity index; HAQ-DI, health assessment questionnaire-disability index, mTSS, modified total Sharp score; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; bDAMRDs, biological disease-modifying antirheumatic drugs; tsDMARDs, target synthetic disease-modifying antirheumatic drugs. Multivariate1, including ITIH3, disease duration, ESR, CRP and radiological joint destruction. Multivariate2, including ITIH3, gender, age, disease duration, ESR, CRP, radiological joint destruction and previous treatment. | ||||||||
| ITIH3 | 1.012 (1.005-1.019) | < 0.001 | 1.018 (1.009-1.029) | < 0.001 | 1.024 (1.013-1.038) | < 0.001 | ||
| Female | 1.436 (0.548-3.875) | 0.462 | 1.137 (0.215-6.436) | 0.880 | ||||
| Age | 1.006 (0.972-1.042) | 0.721 | 1.002 (0.949-1.059) | 0.939 | ||||
| Disease duration | 1.004 (0.999-1.009) | 0.112 | 1.000 (0.993-1.007) | 0.977 | 1.000 (0.993-1.008) | 0.960 | ||
| Active smoking | 0.813 (0.241-2.667) | 0.731 | ||||||
| Positive RF | 1.596 (0.619-4.271) | 0.335 | ||||||
| Positive ACPA | 1.551 (0.619-4.003) | 0.350 | ||||||
| 28TJC | 0.990 (0.918-1.065) | 0.779 | ||||||
| 28SJC | 0.961 (0.865-1.063) | 0.442 | ||||||
| PtGA | 1.002 (0.874-1.150) | 0.972 | ||||||
| PrGA | 1.010 (0.877-1.165) | 0.886 | ||||||
| Pain VAS | 1.036 (0.885-1.215) | 0.660 | ||||||
| ESR | 1.016 (1.003-1.031) | 0.013 | 1.021 (1.000-1.045) | 0.056 | 1.024 (0.999-1.052) | 0.065 | ||
| CRP | 1.009 (0.995-1.026) | 0.213 | 0.986 (0.959-1.015) | 0.321 | 0.986 (0.954-1.022) | 0.403 | ||
| CDAI | 0.995 (0.966-1.026) | 0.761 | ||||||
| HAQ-DI | 1.039 (0.617-1.758) | 0.884 | ||||||
| Physical dysfunction | 1.112 (0.449-2.771) | 0.818 | ||||||
| mTSS | 1.005 (0.996-1.016) | 0.289 | ||||||
| Radiological joint destruction | 1.945 (0.851-4.531) | 0.115 | 1.435 (0.4595-4.463) | 0.530 | 1.833 (0.521-6.576) | 0.344 | ||
| Previous treatment | ||||||||
| Treatment naÏve | 0.804 (0.316-2.013) | 0.641 | 0.805 (0.052-16.06) | 0.881 | ||||
| Glucocorticoids | 1.314 (0.569-3.060) | 0.522 | 3.126 (0.874-13.37) | 0.097 | ||||
| csDMARDs | 1.458 (0.545-4.013) | 0.453 | 0.436 (0.040-5.478) | 0.494 | ||||
| bDAMRDs/tsDMARDs | 1.537 (0.243-12.12) | 0.644 | 1.022 (0.099-10.94) | 0.985 | ||||